LEXICON PHARMACEUTICALS, INC. (LXRX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 41.47M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 358.00K USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $41.47M | $358.00K | (m) |
| 2026-03-31 | (m) | $69.64M | $352.00K | (m) |
| 2025-12-31 | (m) | $49.80M | $274.00K | (m) |
| 2025-09-30 | (m) | $45.86M | $421.00K | (m) |
| 2025-06-30 | (m) | $33.42M | $482.00K | (m) |
| 2025-03-31 | (m) | $6.17M | $615.00K | (m) |
| 2024-12-31 | (m) | $6.00M | $616.00K | (m) |
| 2024-09-30 | (m) | $5.12M | $338.00K | (m) |
| 2024-06-30 | (m) | $3.53M | $274.00K | (m) |
| 2024-03-31 | (m) | $2.20M | $116.00K | (m) |
| 2023-12-31 | (m) | $1.11M | $85.00K | (m) |
| 2023-09-30 | (m) | $438.00K | $15.00K | (m) |
| 2023-06-30 | (m) | $291.00K | $8.00K | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $0.00 | $0.00 | (m) |
| 2022-09-30 | (m) | $0.00 | $0.00 | (m) |
| 2022-06-30 | (m) | $0.00 | $0.00 | (m) |
| 2021-12-31 | (m) | $0.00 | $0.00 | (m) |
| 2021-09-30 | (m) | $23.37M | $0.00 | (m) |
| 2021-06-30 | (m) | $23.37M | $633.00K | (m) |
| 2021-03-31 | (m) | $23.40M | $1.36M | (m) |
| 2020-12-31 | (m) | $23.40M | $1.93M | (m) |
| 2020-09-30 | (m) | $-256.85M | $2.70M | (m) |
| 2020-06-30 | (m) | $29.07M | $2.65M | (m) |
| 2020-03-31 | (m) | $29.90M | $3.25M | (m) |
| 2019-12-31 | (m) | $32.33M | $3.23M | (m) |
| 2019-09-30 | (m) | $289.00M | $3.03M | (m) |
| 2019-06-30 | (m) | $3.65M | $3.00M | (m) |
| 2019-03-31 | (m) | $9.19M | $2.51M | (m) |
| 2018-12-31 | (m) | $26.58M | $2.49M | (m) |
| 2018-09-30 | (m) | $78.86M | (m) | (m) |
| 2018-06-30 | (m) | $98.95M | (m) | (m) |
| 2018-03-31 | (m) | $97.25M | (m) | (m) |
| 2017-12-31 | (m) | $90.33M | (m) | (m) |
| 2017-09-30 | (m) | $80.33M | (m) | (m) |
| 2017-06-30 | (m) | $81.10M | (m) | (m) |
| 2017-03-31 | (m) | $89.14M | (m) | (m) |
| 2016-12-31 | (m) | $83.34M | (m) | (m) |
| 2016-09-30 | (m) | $187.58M | (m) | (m) |
| 2016-06-30 | (m) | $160.43M | (m) | (m) |
| 2016-03-31 | (m) | $140.72M | (m) | (m) |
| 2015-12-31 | (m) | $130.01M | (m) | (m) |
| 2015-09-30 | (m) | $24.22M | (m) | (m) |
| 2015-06-30 | (m) | $24.07M | (m) | (m) |
| 2015-03-31 | (m) | $24.37M | (m) | (m) |
| 2014-12-31 | (m) | $22.85M | (m) | (m) |
| 2014-09-30 | (m) | $2.78M | (m) | (m) |
| 2014-06-30 | (m) | $2.60M | (m) | (m) |
| 2014-03-31 | (m) | $2.14M | (m) | (m) |
| 2013-12-31 | (m) | $2.22M | (m) | (m) |
| 2013-09-30 | (m) | $1.03M | (m) | (m) |
| 2013-06-30 | (m) | $1.16M | (m) | (m) |
| 2013-03-31 | (m) | $1.15M | (m) | (m) |
| 2012-12-31 | (m) | $1.09M | (m) | (m) |
| 2012-09-30 | (m) | $1.21M | (m) | (m) |
| 2012-06-30 | (m) | $1.20M | (m) | (m) |
| 2012-03-31 | (m) | $1.55M | (m) | (m) |
| 2011-12-31 | (m) | $1.85M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $4.91M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $10.70M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |